Literature DB >> 22763895

HER2 as a therapeutic target in the gastric cancer: is it sufficient?

Rupesh Chaturvedi, Amar B Singh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22763895      PMCID： PMC3692359          DOI： 10.1007/s12664-012-0217-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN： 0254-8860


× No keyword cloud information.
  17 in total

Review 1.  Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

Authors:  Joseph Schlessinger
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

Review 2.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

Review 3.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study.

Authors:  Anuradha Sekaran; Raja Sekhar Kandagaddala; Santosh Darisetty; Sandeep Lakhtakia; Santa Ayyagari; Guduru Venkat Rao; Pradeep Rebala; Duvvuru Bhaskara Reddy; Duvvuru Nageshwar Reddy
Journal:  Indian J Gastroenterol       Date:  2012-07-04

Review 6.  The ErbB receptors and their role in cancer progression.

Authors:  Thomas Holbro; Gianluca Civenni; Nancy E Hynes
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Authors:  Maurizio Scaltriti; Federico Rojo; Alberto Ocaña; Judit Anido; Marta Guzman; Javier Cortes; Serena Di Cosimo; Xavier Matias-Guiu; Santiago Ramon y Cajal; Joaquin Arribas; José Baselga
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

Review 9.  Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer.

Authors:  A Tokunaga; M Onda; T Okuda; T Teramoto; I Fujita; T Mizutani; T Kiyama; T Yoshiyuki; K Nishi; N Matsukura
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

Review 10.  Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Authors:  A C Hsieh; M M Moasser
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640
View more
  1 in total

Review 1.  The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.

Authors:  Yu-Ying Lei; Jin-Yu Huang; Qiong-Rui Zhao; Nan Jiang; Hui-Mian Xu; Zhen-Ning Wang; Hai-Qing Li; Shi-Bo Zhang; Zhe Sun
Journal:  World J Surg Oncol       Date:  2017-03-21       Impact factor: 2.754
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.